Cargando…

Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers

Despite strict guidelines for coronavirus disease 2019 (COVID-19), South Korea is facing its fourth pandemic wave. In this study, by using an automated electrochemiluminescence immunoassay assay, we tracked anti-spike protein receptor-binding domain (anti-S-RBD) antibody titer from the second dose t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Seok Ryun, Kim, Namhee, Park, Hyunwoong, Minn, Dohsik, Park, Seungman, Roh, Eun Youn, Yoon, Jong Hyun, Shin, Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110264/
https://www.ncbi.nlm.nih.gov/pubmed/35578582
http://dx.doi.org/10.3346/jkms.2022.37.e135
_version_ 1784709065631334400
author Kwon, Seok Ryun
Kim, Namhee
Park, Hyunwoong
Minn, Dohsik
Park, Seungman
Roh, Eun Youn
Yoon, Jong Hyun
Shin, Sue
author_facet Kwon, Seok Ryun
Kim, Namhee
Park, Hyunwoong
Minn, Dohsik
Park, Seungman
Roh, Eun Youn
Yoon, Jong Hyun
Shin, Sue
author_sort Kwon, Seok Ryun
collection PubMed
description Despite strict guidelines for coronavirus disease 2019 (COVID-19), South Korea is facing its fourth pandemic wave. In this study, by using an automated electrochemiluminescence immunoassay assay, we tracked anti-spike protein receptor-binding domain (anti-S-RBD) antibody titer from the second dose to 2 weeks after the booster dose vaccination. After the second dose, 234 participants had their anti-S-RBD antibody titers decrease over time. We also showed the booster dose (the third dose) increased antibody titer by average 14 (min–max, 2–255)-fold higher compared to the second dose among the 211-booster group participants, therefore, the booster dose could be recommended for low responders to the second dose. Our findings showed a distinct humoral response after booster doses of BNT162b2 mRNA vaccines and may provide further evidence of booster vaccination efficacy. These data will also be helpful in vaccination policy decisions that determine the need for the booster dose.
format Online
Article
Text
id pubmed-9110264
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-91102642022-05-23 Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers Kwon, Seok Ryun Kim, Namhee Park, Hyunwoong Minn, Dohsik Park, Seungman Roh, Eun Youn Yoon, Jong Hyun Shin, Sue J Korean Med Sci Brief Communication Despite strict guidelines for coronavirus disease 2019 (COVID-19), South Korea is facing its fourth pandemic wave. In this study, by using an automated electrochemiluminescence immunoassay assay, we tracked anti-spike protein receptor-binding domain (anti-S-RBD) antibody titer from the second dose to 2 weeks after the booster dose vaccination. After the second dose, 234 participants had their anti-S-RBD antibody titers decrease over time. We also showed the booster dose (the third dose) increased antibody titer by average 14 (min–max, 2–255)-fold higher compared to the second dose among the 211-booster group participants, therefore, the booster dose could be recommended for low responders to the second dose. Our findings showed a distinct humoral response after booster doses of BNT162b2 mRNA vaccines and may provide further evidence of booster vaccination efficacy. These data will also be helpful in vaccination policy decisions that determine the need for the booster dose. The Korean Academy of Medical Sciences 2022-04-21 /pmc/articles/PMC9110264/ /pubmed/35578582 http://dx.doi.org/10.3346/jkms.2022.37.e135 Text en © 2022 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Kwon, Seok Ryun
Kim, Namhee
Park, Hyunwoong
Minn, Dohsik
Park, Seungman
Roh, Eun Youn
Yoon, Jong Hyun
Shin, Sue
Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers
title Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers
title_full Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers
title_fullStr Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers
title_full_unstemmed Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers
title_short Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers
title_sort strong sars-cov-2 antibody response after booster dose of bnt162b2 mrna vaccines in uninfected healthcare workers
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110264/
https://www.ncbi.nlm.nih.gov/pubmed/35578582
http://dx.doi.org/10.3346/jkms.2022.37.e135
work_keys_str_mv AT kwonseokryun strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers
AT kimnamhee strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers
AT parkhyunwoong strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers
AT minndohsik strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers
AT parkseungman strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers
AT roheunyoun strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers
AT yoonjonghyun strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers
AT shinsue strongsarscov2antibodyresponseafterboosterdoseofbnt162b2mrnavaccinesinuninfectedhealthcareworkers